A double-blind trial of clonazepam in the treatment of parkinsonian dysarthria.
We studied the effect of clonazepam in a double-blind trial on 12 parkinsonian patients with hypokinetic dysarthria. Speech samples were judged on 14 of the dimensions used in the Mayo Clinic dysarthria study. Of the 11 patients who completed the study, 10 showed improvement. The effective dosage of clonazepam was 0.25 to 0.5 mg/d with higher dosage than that less effective. Clonazepam has a definite role in the management of parkinsonian dysarthria.
Biary
N
N
Department of Neurology, University of Illinois at Chicago 60612.
Pimental
P A
PA
Langenberg
P W
PW
D000368:Aged; D002986:Clinical Trials as Topic; D002998:Clonazepam / Q000627:therapeutic use*; D004311:Double-Blind Method; D004401:Dysarthria / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D013064:Speech Disorders / Q000188:drug therapy*
D002998:Clonazepam